Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ARCA Biopharma Inc | ABIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.63 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.56 - 3.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 3.63 | USD |
ARCA Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
52.64M | 14.50M | - | 0 | -5.34M | -0.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ARCA Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.19 | 3.75 | 3.13 | 3.43 | 349,374 | 0.44 | 13.79% |
1 Month | 1.76 | 3.88 | 1.6901 | 3.24 | 4,642,895 | 1.87 | 106.25% |
3 Months | 1.60 | 3.88 | 1.57 | 3.23 | 1,538,547 | 2.03 | 126.88% |
6 Months | 1.98 | 3.88 | 1.56 | 3.20 | 727,291 | 1.65 | 83.33% |
1 Year | 1.96 | 3.88 | 1.56 | 3.16 | 372,802 | 1.67 | 85.20% |
3 Years | 3.51 | 3.90 | 1.56 | 2.97 | 228,723 | 0.12 | 3.42% |
5 Years | 5.62 | 22.00 | 1.56 | 7.32 | 395,898 | -1.99 | -35.41% |
ARCA Biopharma Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |